Yes! Secukinumab (Cosentyx) was FDA-approved in 2024 specifically for treating hidradenitis suppurativa, making it one of the newer approved options available.
It works by targeting a protein called IL-17A, which plays a key role in the inflammation associated with HS. Here's a quick overview of how it compares to other Show Full Answer
Yes! Secukinumab (Cosentyx) was FDA-approved in 2024 specifically for treating hidradenitis suppurativa, making it one of the newer approved options available.
It works by targeting a protein called IL-17A, which plays a key role in the inflammation associated with HS. Here's a quick overview of how it compares to other approved biologics for HS:
- Adalimumab (Humira) — targets TNF, the first FDA-approved biologic for HS
- Secukinumab (Cosentyx) — targets IL-17A, approved in 2024
- Bimekizumab-bkzx (Bimzelx) — targets both IL-17A and IL-17F, also approved in 2024
Like all biologics, Cosentyx is given by injection and can increase the risk of certain infections, including tuberculosis. It's generally considered for moderate to severe HS cases.
It's worth having a conversation with your doctor to see if Cosentyx fits your specific situation, symptoms, and health history.
July 2
Join
Your Privacy Choices
